Anti-tumor activity of tebotelimab in lymphoma
cancer, DLBCL
CANCER, DISEASE CHARACTERISTIC
In our survey of LAG-3 expression across cancer types, DLBCL showed frequent and high levels of LAG-3 expression (Supplementary Fig. Baseline demographics and disease characteristics of patients with DLBCLData cutoff: 1 December 2021. ABC, activated B cell; GCB, germinal center B cell.A notable case was that of a 27-year-old man who had developed DLBCL progression after chemotherapy (dose-adjusted R-EPOCH regimen) and investigational CAR-T cell therapy (JCAR017, lisocabtagene maraleucel). This patient experienced a CR after a single dose of tebotelimab (Extended Data Fig. 